NZ758647A - Garp-tgf-β antibodies - Google Patents

Garp-tgf-β antibodies

Info

Publication number
NZ758647A
NZ758647A NZ758647A NZ75864718A NZ758647A NZ 758647 A NZ758647 A NZ 758647A NZ 758647 A NZ758647 A NZ 758647A NZ 75864718 A NZ75864718 A NZ 75864718A NZ 758647 A NZ758647 A NZ 758647A
Authority
NZ
New Zealand
Prior art keywords
tgf
antibodies
antigen binding
garp
complex
Prior art date
Application number
NZ758647A
Other languages
English (en)
Inventor
Der Woning Sebastian Van
Filip Borgions
Torsten Dreier
Lore Mariën
Boeck Gitte De
Stéphanie Lienart
Sophie Lucas
Pierre Coulie
Original Assignee
argenx BV
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV, Univ Catholique Louvain filed Critical argenx BV
Publication of NZ758647A publication Critical patent/NZ758647A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NZ758647A 2017-05-11 2018-05-11 Garp-tgf-β antibodies NZ758647A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES

Publications (1)

Publication Number Publication Date
NZ758647A true NZ758647A (en) 2022-07-29

Family

ID=59201573

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ758647A NZ758647A (en) 2017-05-11 2018-05-11 Garp-tgf-β antibodies

Country Status (35)

Country Link
US (4) US10479829B2 (enExample)
EP (3) EP4086286A1 (enExample)
JP (2) JP7118135B2 (enExample)
KR (2) KR20240065192A (enExample)
CN (1) CN110945027B (enExample)
AU (2) AU2018265241B2 (enExample)
BR (1) BR112019023735A8 (enExample)
CA (1) CA3061841C (enExample)
CL (1) CL2019003211A1 (enExample)
CO (1) CO2019013669A2 (enExample)
CR (1) CR20190561A (enExample)
CY (1) CY1125674T1 (enExample)
DK (1) DK3606961T3 (enExample)
DO (1) DOP2019000285A (enExample)
EC (1) ECSP19087742A (enExample)
ES (1) ES2921015T3 (enExample)
GB (1) GB201707561D0 (enExample)
HR (1) HRP20220787T1 (enExample)
HU (1) HUE059237T2 (enExample)
IL (2) IL270236B2 (enExample)
LT (1) LT3606961T (enExample)
MX (1) MX385670B (enExample)
MY (1) MY199335A (enExample)
NZ (1) NZ758647A (enExample)
PE (1) PE20200618A1 (enExample)
PH (1) PH12019502526A1 (enExample)
PL (1) PL3606961T3 (enExample)
PT (1) PT3606961T (enExample)
RS (1) RS63361B1 (enExample)
RU (1) RU2767784C2 (enExample)
SG (1) SG10201914130VA (enExample)
SI (1) SI3606961T1 (enExample)
SM (1) SMT202200284T1 (enExample)
UA (1) UA125534C2 (enExample)
WO (1) WO2018206790A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
KR20250093432A (ko) 2019-08-28 2025-06-24 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
JPWO2021079958A1 (enExample) 2019-10-25 2021-04-29
TW202135862A (zh) * 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
WO2021231732A1 (en) * 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2021380681A1 (en) * 2020-11-11 2023-06-15 Versapeutics Inc. Antibody variants against wnt receptor ryk
IL303349A (en) * 2020-12-02 2023-08-01 Shanghai Henlius Biotech Inc ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
WO2023225555A1 (en) 2022-05-18 2023-11-23 Vestaron Corporation Pesticidal actx peptide variants
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
EP4561612A1 (en) 2022-07-29 2025-06-04 Abbvie Biotherapeutics Inc. Anti-garp-tgf-beta1/pd-1 combination therapy
KR20250133913A (ko) 2023-01-09 2025-09-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8951793B2 (en) 2008-08-21 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of making an isolated population of FOXP3+ regulatory T cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
WO2014033252A1 (en) 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
NZ717476A (en) 2013-08-01 2022-04-29 Univ Catholique Louvain Anti-garp protein and uses thereof
EP3253796A1 (en) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp protein and uses thereof
CN115869398B (zh) * 2015-09-24 2025-04-22 第一三共株式会社 抗garp抗体
CA3030862A1 (en) * 2016-07-14 2018-01-18 Scholar Rock, Inc. Tgfb antibodies, methods, and uses

Also Published As

Publication number Publication date
EP4282430A2 (en) 2023-11-29
KR20240065192A (ko) 2024-05-14
US20180327487A1 (en) 2018-11-15
PE20200618A1 (es) 2020-03-11
BR112019023735A2 (pt) 2020-06-09
CA3061841C (en) 2022-08-09
US20190375832A1 (en) 2019-12-12
US10479829B2 (en) 2019-11-19
WO2018206790A1 (en) 2018-11-15
CO2019013669A2 (es) 2020-04-01
AU2018265241B2 (en) 2021-11-04
MX385670B (es) 2025-03-18
RS63361B1 (sr) 2022-07-29
SI3606961T1 (sl) 2022-10-28
CR20190561A (es) 2020-04-04
US10793627B2 (en) 2020-10-06
IL270236B2 (en) 2024-02-01
EP4282430A3 (en) 2024-04-03
CN110945027B (zh) 2023-08-01
JP2020519308A (ja) 2020-07-02
AU2021240255A1 (en) 2021-10-28
IL305613A (en) 2023-11-01
EP3606961B8 (en) 2022-07-13
ES2921015T3 (es) 2022-08-16
PH12019502526A1 (en) 2020-07-20
MX2019013490A (es) 2021-08-26
IL270236A (enExample) 2019-12-31
LT3606961T (lt) 2022-07-11
CY1125674T1 (el) 2025-05-09
ECSP19087742A (es) 2020-05-29
JP7118135B2 (ja) 2022-08-15
CN110945027A (zh) 2020-03-31
JP2022169549A (ja) 2022-11-09
CA3061841A1 (en) 2018-11-15
HRP20220787T1 (hr) 2022-09-16
US20210324061A1 (en) 2021-10-21
IL270236B1 (en) 2023-10-01
RU2767784C2 (ru) 2022-03-21
PT3606961T (pt) 2022-07-04
PL3606961T3 (pl) 2022-08-16
RU2019140602A3 (enExample) 2021-07-23
US20200095311A1 (en) 2020-03-26
KR102664663B1 (ko) 2024-05-23
HUE059237T2 (hu) 2022-11-28
SG10201914130VA (en) 2020-03-30
EP4086286A1 (en) 2022-11-09
BR112019023735A8 (pt) 2023-01-31
EP3606961B1 (en) 2022-06-01
CL2019003211A1 (es) 2020-04-24
UA125534C2 (uk) 2022-04-13
EP3606961A1 (en) 2020-02-12
MY199335A (en) 2023-10-24
KR20200027469A (ko) 2020-03-12
SMT202200284T1 (it) 2022-09-14
US10875914B2 (en) 2020-12-29
GB201707561D0 (en) 2017-06-28
DOP2019000285A (es) 2020-07-15
DK3606961T3 (da) 2022-07-04
AU2018265241A1 (en) 2019-11-21
RU2019140602A (ru) 2021-06-11

Similar Documents

Publication Publication Date Title
NZ758647A (en) Garp-tgf-β antibodies
KR102144317B1 (ko) 항-lag-3 항체 및 그것의 사용
CN110099923A (zh) 配对改善的t细胞受体
Ring et al. Targeting of autoantigens to DEC205+ dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice
CN104479020B (zh) 一种抗pd-1人源抗体
AU2002347369A8 (en) Immunotherapeutic methods and systems
CN103748107A (zh) 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a
Harokopakis et al. Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits
ES2642892T3 (es) Protección de vacuna multivalente contra la infección por estafilococo aureus
Flach et al. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori
TWI717880B (zh) Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
RU2510281C2 (ru) ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
CN108239149B (zh) 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
Whaley et al. Emerging antibody-based products
IL116436A0 (en) FCE-PE chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same
WO2019197563A3 (en) Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
Kim et al. Lipoteichoic acid of Streptococcus gordonii as a negative regulator of human dendritic cell activation
WO1993011791A1 (en) Antigenic preparations that stimulate production of antibodies which bind to the pili of type iv piliated bacteria
Medaglini et al. In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii
JP6916216B2 (ja) ファージディスプレイ技術を用いたにきび菌に特異的に結合するヒト抗体およびその用途
KR102639592B1 (ko) 짝짓기가 향상된 t 세포 수용체
DE19634159C1 (de) Induktion einer Tumorimmunität durch Injektion von Hybridzellen
CN103623398B (zh) 猪带绦虫tso45w-4b-tsol18融合基因重组双歧杆菌疫苗制备及鉴定方法
JPH115749A (ja) 癌治療医薬品組成物
AU2022251604B2 (en) Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2024 BY THOMSON REUTERS

Effective date: 20230403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2025 BY THOMSON REUTERS

Effective date: 20240401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2026 BY THOMSON REUTERS

Effective date: 20250402